Pharmaceutical composition comprising telomerase activator and nanoparticles for drug delivery, and composition containing same for prevention, alleviation, or treatment of hair loss
Encapsulating telomerase activators in nanoparticles facilitates effective delivery and activation within hair follicles, addressing the limitations of existing treatments by promoting hair regrowth and pore regeneration in models of androgenic alopecia.
Patent Information
- Application Number
- PCT/KR2024/001466
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-01-31
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for hair loss, particularly androgenic alopecia, are ineffective in reversing hair miniaturization and regrowth due to the inability of telomerase activating substances to penetrate and activate telomerase in aged hair follicle pores, leading to limited hair growth promotion and regeneration.
Encapsulating telomerase activators like TA-65 and GPC within nanobubbles, nanoliposomes, and mesoporous silica nanoparticles to enhance delivery and activation of telomerase in hair follicle pores, promoting regeneration and growth.
The use of nanoparticle-encapsulated telomerase activators significantly increases telomerase activity, leading to regrowth of aged pores and hair, as demonstrated by increased active pores and hair growth in experimental models, outperforming standard lotion applications.
Smart Images

Figure KR2024001466_07112024_PF_FP_ABST
Abstract
Description
Composition for drug delivery comprising a telomerase activator and nanoparticles and composition for preventing, improving or treating hair loss comprising the same
[0001] The present invention relates to a drug delivery composition comprising a telomerase activator and nanoparticles, and a composition comprising the same for preventing, improving, or treating hair loss, and more specifically, to a composition having the effect of promoting the regeneration and growth of pores, which is a nanoliposome, nanosilica particle, or nanobubble composition in which a drug such as a plant extract component TA-65 and its derivatives that increase telomerase activity, and a telomerase activating compound GPC and its derivatives are encapsulated.
[0002] Hair loss generally refers to the loss of thick, dark hair from the scalp. The causes of hair loss are diverse, but genetic factors and androgens, the male hormone, are thought to be important factors. Among them, androgenic alopecia, which accounts for a large proportion of 60-70%, is caused by testosterone being converted to dihydrotestosterone (DHT) by 5-alpha reductase (SRD5A), and the excess dihydrotestosterone binds to the androgenic receptor (AR) of dermal papilla cells (DPC), inducing apoptosis, resulting in hair miniaturization and hair loss. Men who have a high expression of type 2 5-alpha reductase (SRD5A2), which is mainly distributed in the hair papilla and outer root sheath of the hair follicle, or who have high activity of type 2 5-alpha reductase have a higher possibility of developing hair loss because the amount of dihydrotestosterone is relatively higher than that of the average man. Therefore, the key to treating androgenetic alopecia is to lower the amount or activity of type 2 5-alpha reductase and prevent the conversion of testosterone to dihydrotestosterone.
[0003] Telomeres are DNA structures consisting of a repeating DNA hexamer (TTAGGG) sequence found at the ends of chromosomes. They are known to stabilize the structure and function of chromosomes. Telomeres shorten as cells repeatedly replicate their chromosomal DNA. When telomeres shorten below a certain length, cells enter a state of senescence, unable to grow any further. Telomere length can be used as a marker of the degree of cellular aging. Telomeres shorten as organisms age, and are also shortened by stress, smoking, pollution, lack of exercise, and obesity. Furthermore, shorter telomeres are known to increase the incidence of various age-related diseases, including cardiovascular disease. Cellular aging can be seen as inducing aging in human tissues and organs.
[0004] Telomerase is an enzyme protein that catalyzes the addition of telomere repeats to the 3' end of telomeres, thereby repairing telomeres shortened by DNA replication and various external stresses. Since its discovery, most scientists have focused on its role in cancer research. Because telomerase is required for cancer cell growth, telomerase expression was once thought to cause cancer. However, recent studies using telomerase-transgenic mice have shown that high-level telomerase expression does not cause cancer, but rather restores (rejuvenates) bodily functions associated with aging.
[0005] It has been confirmed that gene-knockout mice that lack the telomerase gene are infertile and develop symptoms associated with aging, such as osteoporosis, diabetes, and nerve damage, and age faster than normal mice. On the other hand, when genetically engineered mice that express telomerase only when administered orally with doxycycline were administered doxycycline to high-level telomerase expression after aging, it was shown that brain function, reproductive ability, and the functions of organs such as the spleen, liver, and intestines that had been weakened due to aging were restored. In addition, it was confirmed that hair growth was induced by inducing hair follicle growth and regeneration. These results show that telomerase activation causes changes that regenerate aged pores by inducing the growth and regeneration of pore stem cells that induce pore growth.
[0006] However, the results of studies on genetically engineered animals showing that telomerase activity can reverse various aging phenomena have accelerated the search for telomerase activators that can be directly used in humans, and as a result, various telomerase activators have been discovered.
[0007] Telomerase-activating substances (telomerase activators) can be classified into two types based on their source. The first type is plant extracts and their derivatives with telomerase-activating properties, while the second type is chemical compounds.
[0008] Cycloastragenol and its derivatives, which are components of plants; Cycloastragenol (abbreviated as CAG, chemical formula C30H), which is a component of plants of the genus Astragalus 50O5) is also called TAT2 or GRN665. TA-65 is a telomerase activator containing cycloastragenol, which is extracted and purified using a patented method from the Astragalus plant by TA Science in the United States. Other plant-derived telomerase activators include Genistein from soybeans, extracts from Centella asiatica, and Maslinic acid from olive-pomace oil.
[0009] Among the substances discovered as compounds that activate telomerase, GRN510 (Le Saux et al., 2013) and C3-(L)-valyl-cycloastragenol (US 9,913,852 B2) are derivatives of cycloastragenol.
[0010] Meanwhile, N-propyl-5-(2-thienyl)isoxazole-3-carboxamide (US 2009 / 0143451 Al) and various derivatives have been reported as compounds that increase the expression of telomerase. Guanidinopentyl phenylisoxazolecarboxamide, (chemical formula; C), one of the derivatives of N-propyl-5-(2-thienyl)isoxazole-3-carboxamide 16 H 21 N5O2, abbreviated as GPC), which is known as a representative telomerase activating compound.
[0011] In addition, there are compounds such as AGS499 and AGS500, for which Shi et al (2020) reported telomerase activity.
[0012] There are papers and patents reporting on the recovery of brain function, reproductive ability, spleen, liver, intestines, and other organs weakened by aging, and the improvement of biological functions such as immune activity using the telomerase activator reported above, but there has been no report on the improvement of hair loss and hair growth efficacy by delivering the same substances to pores and activating pore cells. The applicant of the present invention has conducted research and development on whether the telomerase activator has hair loss prevention efficacy.
[0013] The purpose of the present invention is to provide a drug delivery composition using nanobubbles, nanoliposomes, nanoparticles, etc., or a method for preparing the same, and a composition for preventing, improving, or treating hair loss containing the same as an active ingredient, by inducing regrowth of aged hair follicles that have entered a complete resting phase due to aging and have stopped growing hair using a telomerase activator, thereby resuming hair growth.
[0014] The present invention provides nanoparticles encapsulating a telomerase activating substance as a drug for treating hair loss, and a composition containing the same for improving or treating hair loss.
[0015] More specifically, the purpose of the present invention is to provide a composition having the effect of promoting the regeneration and growth of pores, which is a nanoliposome, nanosilica particle, or nanobubble composition encapsulating a drug such as a plant extract component TA-65 and its derivatives that increase telomerase activity, a telomerase-activating compound GPC and its derivatives, etc.
[0016] The present invention relates to a nanoliposome complex, a mesoporous silica nanoparticle complex, or a nanobubble complex in which a telomerase activator is encapsulated.
[0017] The above telomerase activating substance is a telomerase activating substance that increases telomerase expression in cells or increases telomere synthesis enzyme activity, and is a composition for improving or treating hair loss, which includes at least one selected from the group consisting of TA-65, a plant-derived extract component, and GPC among compounds.
[0018] In the present invention, nanobubble, nanoliposome, and nanosilica solutions can be prepared by using TA-65 and GPC at concentrations of 0.2 mg / L to 2 g / L, respectively.
[0019] Additionally, the above-mentioned drug for promoting pore regeneration may have the effect of increasing the expression or enzyme activity of telomerase.
[0020] The above nanoliposomes may contain lecithin, cholesterol and cationic, anionic or zwitterionic phospholipids.
[0021] The above nanobubbles are bubbles with a size of 50 nm to 500 nm created by various methods such as electricity, ultrasound, and pressure, and are preferably bubbles that can enter pores, but may also include those larger than that.
[0022] The above silica nanoparticles are mesoporous silica nanospheres (MSN) having empty porous cavities of 2 nm to 50 nm in size, and among the M41S series silica nanoparticles having uniform cavities of size and volume, the hexagonal MCM-41 (Mobile Crystalline Material-41) is used, but the composition and structure of the silica nanoparticles may vary. In the present invention, 100 nm MCM-41 nanoparticles purchased from Sigma-Aldrich, USA were used as silica nanoparticles.
[0023] The present invention can provide a composition for improving or treating hair loss, which comprises a nanoliposome, nanobubble, or mesoporous silica nanoparticle complex containing a telomerase activating substance.
[0024] The present invention relates to a nanoliposome or mesoporous nanosilica particle or nanobubble combined with a substance that activates telomerase as a component or compound of a plant extract such as TA-65 or GPC, and a composition for improving or treating hair loss containing the same.
[0025] When a solution containing a telomerase activator dissolved in standard toner was applied to aged animals, no improvement in hair loss or hair growth was observed. This finding explains why there have been no previous studies or patents reporting the hair loss-improving effects of telomerase activators.
[0026] However, telomerase activation induces the regeneration of aged hair follicles and the activation of hair follicle stem cells. This has been demonstrated in experiments using genetically engineered mice. Specifically, when the telomerase gene is artificially expressed in telomerase-positive mice after hair follicles have aged and hair growth has ceased due to aging, regrowth of hair follicle stem cells, hair follicle regrowth, and hair growth resume.
[0027] However, the absence of reports that telomerase activating substances induce regrowth of hair follicle stem cells and hair growth suggests that applying telomerase activating substances to the scalp does not allow these substances to enter the hair follicles and activate telomerase, and thus does not induce hair follicle regeneration and thus does not have the effect of promoting hair growth.
[0028] Therefore, it is important to utilize drug delivery vehicles to enhance the delivery efficiency of telomerase-activating substances into pores. The use of nanobubbles, nanoliposomes, porous silica nanoparticles, and the like of the present invention demonstrates the efficacy of telomerase-activating substances as drugs for improving and treating hair loss. It can be used to very effectively treat hair loss caused by aging-related pore aging and hair growth cessation.
[0029] Nanoliposomes, porous silica nanoparticles, and nanobubbles have been attracting attention as drug delivery vehicles, but they have never been used to deliver telomerase activators to aged pores.
[0030] In the present invention, nanobubbles, nanoliposomes, and mesoporous silica nanoparticles containing telomerase-activating agents each exhibited consistent hair growth and pore regrowth effects, albeit to varying degrees. Therefore, the drug-carrier mixtures demonstrate that these compositions, although to varying degrees due to differences in composition, are effective in improving hair loss and as therapeutic agents.
[0031] Figure 1 shows the results of standard toner and a solution containing TA-65 (100 ng / ml) or GPC (100 ng / ml) on 20-month-old C57 / BL6 mice. After removing the hair from the mice, it was confirmed that no hair had grown back for 4 weeks. After that, the skin was applied for 8 weeks, and the hair growth status was checked after 8 weeks. The mice were not limited to 20 months of age. However, aged mice that did not grow back hair after removal were selected and used in the experiment.
[0032] Figure 2 shows a solution generating nanobubbles in triple-distilled water (A), a solution generating nanobubbles in triple-distilled water containing TA-65 (B) or GPC (C), which was applied to the skin of a 20-month-old C57 / BL6 mouse for 8 weeks (3 times a week) after removing the hair and confirming that no hair grew back for 4 weeks, and the hair growth status was confirmed after 8 weeks.
[0033] Figure 3 shows a nanoliposome solution encapsulating nanoliposomes (A), TA-65 (B), or GPC (C) applied to the skin of a 20-month-old C57 / BL6 mouse for 8 weeks (5 times a week) after removing the hair and confirming that no hair had grown back for 4 weeks, and then checking the hair growth status after 8 weeks.
[0034] Figure 4 shows a solution containing nano silica particles (A), TA-65 (B), or GPC (C) applied to the skin of a 20-month-old C57 / BL6 mouse for 8 weeks (5 times a week) after removing the hair and confirming that no hair had grown back for 4 weeks, and then checking the hair growth status after 8 weeks.
[0035] Figure 5 shows the distribution and state of pores after biopsying the skin of the mouse used in Figures 2, 3, and 4, staining with H&E, and photographing it with a microscope (magnification: 40x). The types of pores are indicated as inactive pores (black arrows) and active pores, primary pores (red arrows) and secondary pores (yellow arrows), in Figure 5C. Solution generating nanobubbles (A), nanobubble-TA-65 (B) or nanobubble-GPC (C), nanoliposomes (D), nanoliposomes-TA-65 (E), nanoliposomes-GPC (F), nanosilica particles (G), nano-silica-TA-65 (H), nanosilica-GPC (I).
[0036] Figure 6 shows the increase in active pores caused by a telomerase activator. This is a distribution of the number of active pores (primary pores + secondary pores) excluding inactive pores, with a unit area of 1 square millimeter in H&E-stained skin tissue.
[0037] Figure 7 shows the tissue of a mouse that was biopsied with a nanobubble solution, nanoliposome, or nanosilica solution containing GPC as in Figures 2, 3, and 4, solidified with paraffin, and then cut laterally, and then stained with H&E to observe the depth of pores.
[0038] Figure 8 shows the pore depth caused by GPC, a telomerase activator. Pore depth was measured using a unit area of 20 square millimeters. While skin applied with GPC solutions containing nanobubbles and nanosilica showed similar pore depths, nanoliposomes showed approximately 50% of the pore depths of nanobubbles and nanosilica. In the case of standardized longevity, active pores were barely observed, making statistical data impossible.
[0039] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are intended only to illustrate the present invention, and the scope of the present invention is not limited by these examples.
[0040] Hereinafter, the present invention will be described in detail through preferred embodiments and comparative examples of the present invention.
[0041]
[0042] [Comparative Example 1]
[0043] A solution was prepared by dissolving TA-65 (100 ng / ml) in standard lotion toner (99.5% ethanol, 1% carbomer solution, reverse osmosis water, 1,2-hexanediol) at a concentration of 100 mg / L.
[0044] [Comparative Example 2]
[0045] A solution was prepared by dissolving GPC (100 ng / ml) in standard lotion water (99.5% ethanol, 1% carbomer solution, reverse osmosis water, 1,2-hexanediol) at a concentration of 100 mg / L.
[0046]
[0047] [Experimental Example 1] Hair growth efficacy of TA-65 and GPC dissolved in standard toner
[0048] To prepare animals whose hair growth ceases due to aging of the follicles, C57 / BL6 mice are first shaved when they reach approximately 20 months of age (not limited to 20 months). Mice that do not grow hair for 4 weeks after shaved are selected, as this indicates that the follicles have aged and entered a complete telogen (a state in which hair production has ceased).
[0049] The solutions of Comparative Examples 1 and 2 were applied 5 times a week for 8 weeks to the shaved skin of aged animals in which no hair growth was observed for 4 weeks after hair removal, and the condition of hair growth was observed from 8 weeks to 16 weeks. Referring to Fig. 1, (A) is a case where a standard toner was applied, (B) is a case where the solution of Comparative Example 1 was applied, and (C) is a case where the solution of Comparative Example 2 was applied. TA-65 and GPC dissolved in the standard toner did not induce hair growth in aged animals.
[0050]
[0051] The hair growth efficacy of TA-65 and GPC by nanobubbles was confirmed through Example 1 below.
[0052] [Example 1]
[0053] - Creation of nanobubble solution containing TA-65
[0054] After dissolving TA-65 in tertiary distilled water at a concentration of 100 mg / L, the solution was injected into a nanobubble housing and electricity of approximately 200 watts was applied for 20 minutes to prepare a solution in which nanobubbles containing TA-65 were generated.
[0055] [Example 2]
[0056] - Creation of nanobubbles containing GPC
[0057] After dissolving GPC in tertiary distilled water at a concentration of 100 mg / L, the solution was injected into a nanobubble housing and electricity of approximately 200 watts was applied for 20 minutes to prepare a solution in which nanobubbles containing GPC were generated.
[0058] And as a control, a solution in which nanobubbles were generated was prepared using triple distilled water that did not contain either TA-65 or GPC.
[0059]
[0060] [Experimental Example 2]
[0061] 1. Experiment on the solution in which nanobubbles were created
[0062] As shown in Fig. 2 (A), mice that were applied with a solution that generated nanobubbles in tertiary distilled water showed no particular skin lesions even after 16 weeks. In addition, the solution that generated nanobubbles was applied 5 times a week for 8 weeks to the hair-lossed skin of aged animals that had not observed hair growth for 4 weeks after hair removal, and the condition of hair growth was observed after 8 weeks, but no hair regrowth was observed even after a total of 16 weeks.
[0063] To examine the pore status of animal skin, a 4-mm skin biopsy was taken from the lower back of a C57 / BL6 mouse. The biopsy was preserved in a 10% formalin solution for 16 hours and then solidified using paraffin as an embedding agent. Horizontal sections were made with a dissecting knife, and the paraffin was removed using xylene. The tissue was stained with hematoxylin-eosin (H&E) to observe the morphology (regressed pores, primary pores, and secondary pores) and number of pores. Furthermore, vertical sections were made simultaneously with horizontal sections to observe the pore depth (length). No abnormalities were detected in H&E staining, but minimal pore enlargement was observed, and pores that appeared to have regressed were observed (Figure 5A).
[0064] 2. Experiments on the solutions of Examples 1 and 2
[0065] After 8 weeks of application of the nanobubble solution of Example 1 containing TA-65 and the nanobubble solution of Example 2 containing GPC, hair growth was observed in almost all of the hair-removed skin areas after 16 weeks (B, C of Fig. 2).
[0066] Therefore, skin biopsies were taken from these mice to observe the pores (Figs. 5B, C), and the number of pores was significantly increased compared to Fig. 5(A). However, the pores in Fig. 5(C) are larger and more densely packed compared to Fig. 5(B).
[0067]
[0068] [Example 3]
[0069] - Production of nano liposome solution containing TA-65
[0070] The composition of the cationic liposome used in the present invention is as follows: dimyristoylphosphatidylcholine, N-(2,3-dioleoyloxy-1-propyl) trimethylammonium methyl sulfate, and cholesterol (50:10:40 mol%).
[0071] - The method for producing liposomes is as follows.
[0072] First, the lipid is dissolved in a chloroform / methanol (3:1) solution and then dried under vacuum in an evaporator.
[0073] Prepare a drug solution by dissolving TA-65 at a concentration of 100 mM in a solution of 10 mM N-[2-hydroxyethyl]piperazine-N0-[2-ethanesulphonic acid] + 150 mM NaCl (pH=7.5, readjusted with sodium hydroxide after dissolving the drug).
[0074] The lipid solid was added to 2 ml of drug solution at 60°C to make a solution with a lipid concentration of 50 mM, and the freezing and thawing process was repeated three times. Then, the solution was extruded through polycarbonate filters with 400 nm pores to make a nanoliposome solution encapsulating TA-65.
[0075] [Example 4]
[0076] - Creation of nano liposome solution containing GPC
[0077] A nano liposome solution encapsulating GPC was prepared in the same manner as in Example 1 above, except that GPC was used instead of TA-65 during the process of preparing the nano liposome solution encapsulating TA-65.
[0078] And as a control, a nanoliposome solution containing neither TA-65 nor GPC was prepared.
[0079]
[0080] To confirm the hair growth efficacy of TA-65 or GPC entrapped in nano liposomes, Experimental Example 3 below was conducted.
[0081]
[0082] [Experimental Example 3]
[0083] 1. Experiment on the solution in which nanoliposomes were produced
[0084] The solution containing nano liposomes did not cause any particular lesions on the skin even after 16 weeks (Fig. 3A), and no abnormalities were found in H&E staining, but pores were almost non-existent, and pores that appeared to have degenerated were observed (Fig. 5D).
[0085] Additionally, mice that did not show hair growth for 4 weeks after hair removal were selected, and these mice did not show hair re-growth even after 16 weeks (Fig. 3A).
[0086] 2. A solution containing nano liposomes encapsulating TA-65 or GPC of Examples 3 and 4 was applied 5 times a week for 8 weeks to the hair-lossed skin of aged animals in which no hair growth was observed for 4 weeks after hair removal, and the condition of hair growth was observed after 8 weeks.
[0087] However, nanoliposome solutions containing TA-65 or GPC of Examples 3 and 4 at a concentration of 60 mg / L showed hair growth in almost all areas of the shaved skin after 16 weeks of application for 8 weeks (Fig. 3, B, C). Accordingly, skin biopsies of these mice were taken to observe the pores (Fig. 5, E, F), and the number of pores was significantly increased compared to Fig. 5, (D). However, the pores of Fig. 5, (F), were larger and denser than those of Fig. 5, (E).
[0088]
[0089] [Example 5]
[0090] TA-65 was reacted with the above MCM-41 for 48 hours with constant stirring to prepare a silica nanoparticle solution containing TA-65 (300 mg / L, TA-65 60 mg / L + MCM-41 240 mg / L).
[0091] [Example 6]
[0092] GPC was reacted with the above MCM-41 for 48 hours with constant stirring to prepare a silica nanoparticle solution (300 mg / L, GPC 60 mg / L + MCM-41 240 mg / L) containing GPC.
[0093] And as a control, a nano silica solution containing neither TA-65 nor GPC was prepared.
[0094]
[0095] To confirm the hair growth efficacy of TA-65 or GPC captured in nano silica, Experimental Example 4 below was conducted.
[0096]
[0097] [Experimental Example 4]
[0098] 1. Mice that were applied with a solution containing mesoporous silica nanoparticles did not develop any particular skin lesions even after 16 weeks (Fig. 4A), and no abnormalities were found in H&E staining, but pores were almost absent, and pores that appeared to have degenerated were observed (Fig. 5G). In addition, mice that did not show any hair growth for 4 weeks after hair removal were selected, and these mice did not show any hair regeneration even after 16 weeks (Fig. 4A).
[0099] 2. However, in the solution containing TA-65 or GPC of Examples 5 and 6 at a concentration of 60 mg / L, hair growth progressed in almost all areas of the depilated skin after 16 weeks of application for 8 weeks (Fig. 4, B, C). Therefore, skin biopsies of these mice were taken to observe the pores (Fig. 5, H, I), and compared to Fig. 5 (G), the number of pores increased significantly, but the pores of Fig. 5 (I) were larger and denser than those of Fig. 5 (H).
[0100]
[0101] Meanwhile, Fig. 6 shows the increase in active pores due to telomerase activating substances, and is a distribution diagram of the number of active pores (primary pores + secondary pores) excluding inactive pores per square millimeter in H&E-stained skin tissue. In Fig. 5 (C), representative pores as inactive pores, primary pores, and secondary pores are indicated with black arrows, light blue arrows, and yellow arrows, respectively, and it was difficult to find active pores in the skin of aged animals to which telomerase activating substances (TA-65 and GPC) dissolved in toner were applied.
[0102] However, when telomerase activating substances bound to or entrapped in nanobubbles, nanoliposomes, or porous silica nanoparticles were applied, a clear increase in the number of active pores in animal skin was observed.
[0103] Fig. 7 shows the results of observing the pore depth by biopsying the mouse skin, which was solidified with paraffin after applying a nanobubble solution (B), nanoliposome (C), or nanosilica (C) solution containing GPC as in Figs. 2, 3, and 4, and then cutting the tissue laterally and performing H&E staining, and Fig. 8 shows the results of measuring the pore depth by GPC, a telomerase activating substance, with a unit area of 20 square millimeters. As can be confirmed in Figs. 7 and 8, it was confirmed that the pore depth of the nanobubble solution (B), nanoliposome (C), or nanosilica (D) solution containing GPC was greater than that of the toner (A). The nanoliposome solution (C) containing GPC showed a pore depth of about 50% of that of the nanobubble solution (B) containing GPC and the nanosilica (D) solution, while in the case of the standard toner, active pores were hardly observed, so no statistical data could be obtained.
[0104]
[0105] In the examples discussed above, examples were presented in which nanobubble, nanoliposome, and nanosilica solutions were prepared with TA-65 and GPC at concentrations of 60 to 100 mg / L, respectively, but the present invention is not limited thereto, and a concentration of 0.2 mg / L to 2 g / L may preferably be used.
[0106]
[0107] The present invention described above is merely exemplary, and those skilled in the art will readily appreciate that various modifications and equivalent other embodiments are possible. Therefore, it will be readily understood that the present invention is not limited to the forms mentioned in the detailed description above. Accordingly, the true technical protection scope of the present invention should be defined by the technical spirit of the appended claims. Furthermore, the present invention should be understood to include all modifications, equivalents, and alternatives within the spirit and scope of the present invention as defined by the appended claims.
[0108] A drug delivery composition comprising a telomerase activator and nanoparticles and a composition for preventing, improving or treating hair loss comprising the same have industrial applicability.
Claims
1. Telomerase activator; and nanoparticles; A composition for preventing, improving or treating hair loss, characterized by comprising:
2. In paragraph 1, A composition for preventing, improving or treating hair loss, characterized in that the telomerase activator is at least one of cycloastragenol, guanidinopentylisoxazolecarboxamide, GRN510, AGS-500, genistein, Centella asiatica extract and maslinic acid.
3. In paragraph 1, The above nanoparticles are at least one of nanobubbles, nanoliposomes and nanosilica, A composition for preventing, improving or treating hair loss, characterized in that the telomerase activator is a complex structure encapsulated or captured in the nanoparticles.
Citation Information
Patent Citations
Compounds that increase telomerase reverse transcriptase (TERT) expression and methods for using the same
US20090143451A1
Method of treating and preventing secondary hyperparathyroidism
US9913852B2
Nanoliposome-microbubble assemblies encapsulating a durg for the treatment of androgenic alopecia, and composition comprising the same for improving or treating hair loss
KR101918250B1
Telomerase activating compounds and methods of use thereof
KR1020160051682A
Efficient inverse molecular design method
KR1020220051940A
Cited By
Product, system and method of cell cultivation
US12668774B2
Culture media based on protein hydrolysate and a process for preparing thereof
US12686847B2
Pet food, methods and devices for producing pet food
US12772996B2
